• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lineage Cell Therapeutics Inc (NY: LCTX )

    0.8221 -0.0079 (-0.95%)
    Streaming Delayed Price Updated: 2:35 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Lineage Cell Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 Next >
    Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility
    Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California. 
    Via Benzinga
    The Three Best Anti-Aging Stocks to Buy in September
    These three anti-aging stocks could see recovery ahead. ATHX, LCTX, and UBX can make great long-term investments 
    Via InvestorPlace
    Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed
    According to data from Benzinga Pro, during Q2, Lineage Cell Therapeutics's (AMEX:LCTX) reported sales totaled $4.55 million. Despite a 4.38% increase in earnings, the company posted a loss of $6.78... 
    Via Benzinga
    Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Recap: Lineage Cell Therapeutics Q2 Earnings
      Lineage Cell Therapeutics (AMEX:LCTX) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
    Upgrades 
    Via Benzinga
    Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Cell Therapeutics: Q1 Earnings Insights
    Lineage Cell Therapeutics (AMEX:LCTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Earnings Preview: Lineage Cell Therapeutics
    Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that... 
    Via Benzinga
    Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
    Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
    Via Benzinga
    RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Insiders Buying These 4 Penny Stocks
    The Nasdaq Composite gained around 60 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
    Via Benzinga
    Insiders Buy Over $1.3M Of 4 Penny Stocks
    The Dow Jones tumbled more than 150 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
    Via Benzinga
    Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Cell Therapeutics's Return On Capital Employed Insights
    Benzinga Pro data, Lineage Cell Therapeutics (AMEX:LCTX) reported Q4 sales of $1.20 million. Earnings fell to a loss of $29.19 million, resulting in a 272.61% decrease from last... 
    Via Benzinga
    Lineage Cell Therapeutics: Q4 Earnings Insights
    Lineage Cell Therapeutics (AMEX:LCTX) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement.... 
    Via Benzinga
    RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.